Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders.
The treatment of paraneoplastic neurological syndromes (e.g., tumor therapy, immunosuppressive therapy, plasmapheresis) rarely leads to an improvement in the neurological symptoms. We treated four patients suffering from paraneoplastic neurological syndromes with intravenous immunoglobulins. All four had high titers of antineuronal antibodies in serum and CSF. Two of the patients, one suffering from paraneoplastic cerebellar degeneration and the other from paraneoplastic brain stem encephalitis and polyneuropathy, received intravenous immunoglobulin treatment within 3 weeks of the onset of neurological symptoms. Both patients showed clinical improvement within 2 weeks after the initiation of therapy. They also showed a decline in the intrathecal antibody synthesis of the antineuronal antibody. Two other patients, who had suffered from paraneoplastic neuropathy for 3 and 6 months showed no improvement with the intravenous immunoglobulin therapy. In these cases there was no effect on intrathecal antibody synthesis. When started early, intravenous immunoglobulins may be of therapeutical value in treating paraneoplastic neurological syndromes. Specific intrathecal antibody synthesis may be a better measure of clinical course that autoantibody serum titers.
Blaes
F
F
Department of Neurology, University of the Saarland, Homburg, Germany. nefbla@krzsun.med-rz.uni-sb.de
Strittmatter
M
M
Merkelbach
S
S
Jost
V
V
Klotz
M
M
Schimrigk
K
K
Hamann
G F
GF
D000328:Adult; D000906:Antibodies / Q000134:cerebrospinal fluid; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000276:immunology / Q000628:therapy*; D010257:Paraneoplastic Syndromes / Q000276:immunology / Q000628:therapy*
D000906:Antibodies; D016756:Immunoglobulins, Intravenous